Type 1 receptor tyrosine kinases are differentially phosphorylated in mammary carcinoma and differentially associated with steroid receptors.

No abstract is available for this paper.

• Publication year

  1996

• Venue

  American Journal of Pathology

• Publication date

  1996-02-01

• Fields of study

  Biology, Medicine

• Identifiers
  PMID 8579117PMCID PMC1861670
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• [Prognostic factors in breast cancer].

  1998cited by this paper
• Betacellulin activates the epidermal growth factor receptor and erbB-4, and induces cellular response patterns distinct from those stimulated by epidermal growth factor or neuregulin-beta.

  1996cited by this paper
• The cellular response to neuregulins is governed by complex interactions of the erbB receptor family

  1995cited by this paper
• Epiregulin

  1995cited by this paper
• Activation state-specific monoclonal antibody detects tyrosine phosphorylated p185neu/erbB-2 in a subset of human breast tumors overexpressing this receptor.

  1995cited by this paper
• The erbB3 gene product is a receptor for heregulin.

  1994cited by this paper
• Sensitivity of HER-2/neu antibodies in archival tissue samples: potential source of error in immunohistochemical studies of oncogene expression.

  1994cited by this paper
• Receptor blockade with monoclonal antibodies as anti-cancer therapy.

  1994cited by this paper
• NDF/heregulin stimulates the phosphorylation of Her3/erbB3

  1994cited by this paper
• The biology of erbB-2/neu/HER-2 and its role in cancer.

  1994cited by this paper
• Ligand-specific activation of HER4/p180erbB4, a fourth member of the epidermal growth factor receptor family.

  1993cited by this paper
• Betacellulin: a mitogen from pancreatic beta cell tumors.

  1993cited by this paper
• A novel transcription factor, OB2‐1, is required for overexpression of the proto‐oncogene c‐erbB‐2 in mammary tumour lines.

  1993cited by this paper
• Neu differentiation factor (heregulin) induces expression of intercellular adhesion molecule 1: implications for mammary tumors.

  1993cited by this paper
• Heregulin induces tyrosine phosphorylation of HER4/p180erbB4

  1993cited by this paper
• Glial growth factors are alternatively spliced erbB2 ligands expressed in the nervous system

  1993cited by this paper
• Antiserum raised against a synthetic phosphotyrosine-containing peptide selectively recognizes p185neu/erbB-2 and the epidermal growth factor receptor.

  1992cited by this paper
• Difference in the response of neu and ras oncogene-induced rat mammary carcinomas to early and late ovariectomy.

  1992cited by this paper
• Transcriptional repression of the neu protooncogene by estrogen stimulated estrogen receptor.

  1992cited by this paper
• Prognosis and treatment decisions in patients with breast cancer without axillary node involvement

  1992cited by this paper
• A ligand for the erbB-2 oncogene product (gp30) induces differentiation of human breast cancer cells.

  1992cited by this paper
• Isolation of the neu/HER-2 stimulatory ligand: a 44 kd glycoprotein that induces differentiation of mammary tumor cells.

  1992cited by this paper
• Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease.

  1992cited by this paper
• Identification of Heregulin, a Specific Activator of p185erbB2

  1992cited by this paper
• Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group.

  1992cited by this paper
• Characterization of a growth factor that binds exclusively to the erbB-2 receptor and induces cellular responses.

  1992cited by this paper
• Synthetic phosphopeptide immunogens yield activation-specific antibodies to the c-erbB-2 receptor.

  1992cited by this paper
• Prognostic factors in breast cancer.

  1992cited by this paper
• A heparin-binding growth factor secreted by macrophage-like cells that is related to EGF

  1991cited by this paper
• Follow-up study of HER-2/neu amplification in primary breast cancer.

  1991cited by this paper
• Mechanistic aspects of the opposing effects of monoclonal antibodies to the ERBB2 receptor on tumor growth.

  1991cited by this paper
• Antiphosphotyrosine antibodies in oncogene and receptor research.

  1991cited by this paper
• Heterodimerization of the erbB-1 and erbB-2 receptors in human breast carcinoma cells: a mechanism for receptor transregulation.

  1990cited by this paper
• The amphiregulin gene encodes a novel epidermal growth factor-related protein with tumor-inhibitory activity

  1990cited by this paper
• HER-2/neu amplification predicts poor survival in node-positive breast cancer.

  1990cited by this paper
• HER-2/neu oncogene expression and proliferation in breast cancers.

  1990cited by this paper
• p185neu is phosphorylated on tyrosine in human primary breast tumors which overexpress neu/erbB-2.

  1990cited by this paper
• Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: prognostic significance of erbB-2 protein overexpression in primary breast cancer.

  1990cited by this paper
• Intermolecular association of the p185neu protein and EGF receptor modulates EGF receptor function.

  1990cited by this paper
• Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer.

  1989cited by this paper
• Mechanisms of growth control in normal and malignant breast epithelium.

  1989cited by this paper
• The evaluation of estrogen receptor in primary breast carcinoma by computer-assisted image analysis.

  1988cited by this paper
• Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene.

  1988cited by this paper
• EGF‐stimulated tyrosine phosphorylation of p185neu: a potential model for receptor interactions.

  1988cited by this paper
• Overexpression of the human EGF receptor confers an EGF-dependent transformed phenotype to NIH 3T3 cells.

  1987cited by this paper
• Increased expression of the putative growth factor receptor p185HER2 causes transformation and tumorigenesis of NIH 3T3 cells.

  1987cited by this paper
• Overexpression of the EGF receptor‐related proto‐oncogene erbB‐2 in human mammary tumor cell lines by different molecular mechanisms.

  1987cited by this paper
• Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.

  1987cited by this paper
• Epidermal growth factor receptors on human breast cancers

  1985cited by this paper
• Progesterone receptors as a prognostic factor in stage II breast cancer.

  1983cited by this paper
• Progesterone receptors as a prognostic factor in Stage II breast cancer.

  1983cited by this paper
• Multiple hormone interactions in the developmental biology of the mammary gland.

  1980cited by this paper
• Predicting response to endocrine therapy in human breast cancer: a hypothesis.

  1975cited by this paper

• The Yin and Yang of ERBB4: Tumor Suppressor and Oncoprotein

  2022cites this paper
• A Review of HER4 (ErbB4) Kinase, Its Impact on Cancer, and Its Inhibitors

  2021cites this paper
• A genetic variant of miR‐335 binding site in the ERBB4 3′‐UTR is associated with prognosis of ovary cancer

  2018cites this paper
• ErbB4 3′-UTR Variant (c.*3622A>G) is Associated with ER/PR Negativity and Advanced Breast Cancer

  2018cites this paper
• ErbB4 receptor polymorphism 2368A>C and risk of breast cancer.

  2018cites this paper
• The association between rs1972820 and the risk of breast cancer in Isfahan population

  2017cites this paper
• HER4 rs1595065 3'UTR Variant is a Possible Risk Factor for HER2 Positivity Among Breast Cancer Patients

  2016cites this paper
• rs11895168 C allele and the increased risk of breast cancer in Isfahan population.

  2016cites this paper
• Purdue Research Foundation

  2015cites this paper
• ERBB4 Promoter Polymorphism Is Associated with Poor Distant Disease-Free Survival in High-Risk Early Breast Cancer

  2014cites this paper
• ERBB4 mutations in cancer and amyotrophic lateral sclerosis

  2014cites this paper
• Multiple Functional Motifs Are Required for the Tumor Suppressor Activity of a Constitutively-Active ErbB4 Mutant

  2013cites this paper
• Multiple Functional Motifs Are Required for the Tumor Suppressor Activity of a Constitutively-Active ErbB4 Mutant

  2013cites this paper
• Immunohistochemical analysis of the monoclonal antibody 4B5 in breast tissue expressing human epidermal growth factor receptor 4 (HER4)

  2013cites this paper
• Epiregulin induces human SK-N-BE cell differentiation through ERK1/2 signaling pathway

  2013cites this paper
• Landscape of EGFR signaling network in human cancers: biology and therapeutic response in relation to receptor subcellular locations.

  2012cites this paper
• Proteolytic Processing of ErbB4 in Breast Cancer

  2012cites this paper
• Dihydrotestosterone upregulates the expression of epidermal growth factor receptor and ERBB2 in androgen receptor-positive bladder cancer cells.

  2011cites this paper
• Potential of ErbB4 antibodies for cancer therapy.

  2010cites this paper
• Role of ErbB2 and ErbB4 in Cancer Growth, Prognosis and as Targets for Immunotherapy

  2010cites this paper
• Real‐time quantitative polymerase chain reaction (qPCR) analysis with fluorescence resonance energy transfer (FRET) probes reveals differential expression of the four ERBB4 juxtamembrane region variants between medulloblastoma and pilocytic astrocytoma

  2009cites this paper
• Role of ErbB4 in Breast Cancer

  2008cites this paper
• Cytogenetic analysis of HER1/EGFR, HER2, HER3 and HER4 in 278 breast cancer patients

  2008cites this paper
• HER4 Intracellular Domain (4ICD) Activity in the Developing Mammary Gland and Breast Cancer

  2008cites this paper
• A Novel Polymorphism in the Promoter Region of ERBB4 Is Associated with Breast and Colorectal Cancer Risk

  2007cites this paper
• ANovel Polymorphism in the Promoter Region of ERBB4 Is Associated with Breast and Colorectal Cancer Risk

  2007cites this paper
• Association of Wwox with ErbB 4 in Breast Cancer

  2007cites this paper
• Association of Wwox with ErbB4 in breast cancer.

  2007cites this paper
• HER4 D-box sequences regulate mitotic progression and degradation of the nuclear HER4 cleavage product s80HER4.

  2007cites this paper
• Dimérisation du domaine transmembranaire des récepteurs de la famille ErbB/HER : étude par simulations de dynamique moléculaire

  2007cites this paper
• HER 4 D-Box Sequences Regulate Mitotic Progression and Degradation of the Nuclear HER 4 Cleavage Product s 80 HER 4

  2007cites this paper
• Novel Signaling Pathways in Breast Cancer

  2006cites this paper
• Emerging therapies in gastrointestinal cancers.

  2006cites this paper
• Nuevos mecanismos de tumorgènesis del protooncogén HER2. Implicaciones terapéuticas en cáncer de mama

  2006cites this paper
• EGFR signaling pathway in breast cancers: from traditional signal transduction to direct nuclear translocalization

  2006cites this paper
• The Epidermal Growth Factor Receptor Pathway as a Selective Molecular-Targeted Treatment in Human Breast Cancer

  2006cites this paper
• Coregulation of estrogen receptor by ERBB4/HER4 establishes a growth-promoting autocrine signal in breast tumor cells.

  2006cites this paper
• ErbB 4 increases the proliferation potential of human lung cancer cells and its blockage can be used as a target for anti-cancer therapy

  2006cites this paper
• ErbB4 increases the proliferation potential of human lung cancer cells and its blockage can be used as a target for anti‐cancer therapy

  2006cites this paper
• Phosphorylation of ErbB4 on tyrosine 1056 is critical for ErbB4 coupling to inhibition of colony formation by human mammary cell lines.

  2006cites this paper
• The diverse signaling network of EGFR, HER2, HER3 and HER4 tyrosine kinase receptors and the consequences for therapeutic approaches.

  2005cites this paper
• Anilinodialkoxyquinazolines: screening epidermal growth factor receptor tyrosine kinase inhibitors for potential tumor imaging probes.

  2005cites this paper
• The era of ErbB-receptor-targeted therapies: advances toward personalized medicine.

  2005cites this paper
• Growth of Breast Cancer Cells Regulated − Cleavable ErbB 4 Isoform in Estrogen Receptor

  2005cites this paper
• Cleavable ErbB4 isoform in estrogen receptor-regulated growth of breast cancer cells.

  2005cites this paper
• The role of the Raf/MAP kinase pathway in the development of androgen-insensitive prostate cancer.

  2005cites this paper
• Vitamin D receptor status alters mammary gland morphology and tumorigenesis in MMTV-neu mice.

  2004cites this paper
• secErbB4-26/549 antagonizes ligand-induced ErbB4 tyrosine phosphorylation.

  2004cites this paper
• The type 1 growth factor receptor family: new ligands and receptors and their role in breast cancer

  2004cites this paper
• ErbB-4: mechanism of action and biology.

  2003cites this paper
• Novel therapeutic strategies targeting the epidermal growth factor receptor (EGFR) family and its downstream effectors in breast cancer.

  2003cites this paper
• ErbBs in mammary development.

  2003cites this paper
• A constitutively active ErbB4 mutant inhibits drug-resistant colony formation by the DU-145 and PC-3 human prostate tumor cell lines.

  2003cites this paper
• Phosphorylation state-specific antibodies: applications in investigative and diagnostic pathology.

  2003cites this paper
• The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides.

  2002cites this paper
• Type 1 Protein Tyrosine Kinases in Breast Carcinoma: A Review

  2002cites this paper
• Constitutively active ErbB4 and ErbB2 mutants exhibit distinct biological activities.

  2002cites this paper
• Constitutively Active ErbB 4 and ErbB 2 Mutants Exhibit Distinct Biological Activities 1

  2002cites this paper
• Respectively , in Human Breast Cancer Associate with Unfavorable and Favorable Biomarkers , γ and Estrogen-related Receptor α Estrogen-related Receptor Updated

  2002influential citation
• Estrogen-related receptor alpha and estrogen-related receptor gamma associate with unfavorable and favorable biomarkers, respectively, in human breast cancer.

  2002cites this paper
• Estrogen-related Receptor α and Estrogen-related Receptor γ Associate with Unfavorable and Favorable Biomarkers, Respectively, in Human Breast Cancer

  2002cites this paper
• Mechanisms of Resistance to Endocrine Therapy

  2002cites this paper
• Molecular characterization of breast cancer cell lines by expression profiling

  2002cites this paper
• Epidermal growth factor receptor (EGFR) as a prognostic marker: an immunohistochemical study on 315 consecutive breast carcinoma patients.

  2002cites this paper
• ErbB-4: a receptor tyrosine kinase

  2002cites this paper
• EGFR family expression in breast carcinomas. c‐erbB‐2 and c‐erbB‐4 receptors have different effects on survival

  2002cites this paper
• Expression and clinical significance of erb-B receptor family in hepatocellular carcinoma

  2001cites this paper
• HER2: The Neu Prognostic Marker for Breast Cancer

  2001cites this paper
• Pathobiologic findings in DCIS of the breast: morphologic features, angiogenesis, HER-2/neu and hormone receptors.

  2001cites this paper
• Type 1 Protein Tyrosine Kinases in Chinese Breast Carcinomas

  2001cites this paper
• Expression of EGFR Family and Steroid Hormone Receptors in Ductal Carcinoma in situ of the Breast

  2001cites this paper
• HER2: the neu prognostic marker for breast cancer.

  2001cites this paper
• Biological and clinical significance of her2 overexpression in Breast Cancer

  2001cites this paper
• Estrogen receptor-alpha and C-ERBB-4 expression in breast carcinomas.

  2001cites this paper
• Estrogen receptor-α and C-ERBB-4 expression in breast carcinomas

  2001cites this paper
• Epidermal Growth Factor-Related Peptides in Endocrine Neoplasias

  2000cites this paper
• C-erb-B2 expression and response to treatment in metastatic breast cancer

  2000cites this paper
• Expression of erbB Receptors and their Ligands in Breast Cancer: Implications to Biological Behavior and Therapeutic Response

  2000cites this paper
• Interaction between protein tyrosine phosphatase and protein tyrosine kinase is involved in androgen-promoted growth of human prostate cancer cells

  2000cites this paper
• Role of HER2 gene overexpression in breast carcinoma

  2000cites this paper
• Expression of c‐erbB receptors, heregulin and oestrogen receptor in human breast cell lines

  2000cites this paper
• c-erbB-4 protein expression in human breast cancer

  2000cites this paper
• Molecular mechanisms underlying ErbB2/HER2 action in breast cancer

  2000influential citation
• Tyrosine kinase signalling in breast cancer: ErbB family receptor tyrosine kinases

  2000cites this paper
• Immunohistochemical expression of internal and external ErbB‐2 domains in invasive breast cancer

  1999cites this paper
• c-Src, receptor tyrosine kinases, and human cancer.

  1999cites this paper
• Advances in Brief Activation of Mitogen-Activated Protein Kinase Associated with Prostate Cancer Progression 1

  1999cites this paper
• Ribozyme-mediated down-regulation of ErbB-4 in estrogen receptor-positive breast cancer cells inhibits proliferation both in vitro and in vivo.

  1999cites this paper
• Activation of mitogen-activated protein kinase associated with prostate cancer progression.

  1999cites this paper
• Expression of dominant-negative ErbB2 in the mammary gland of transgenic mice reveals a role in lobuloalveolar development and lactation

  1999influential citation
• Erbb4 Signaling in the Mammary Gland Is Required for Lobuloalveolar Development and Stat5 Activation during Lactation

  1999cites this paper
• Activation of ErbB4 by the Bifunctional Epidermal Growth Factor Family Hormone Epiregulin Is Regulated by ErbB2*

  1998cites this paper
• Type 1 protein tyrosine kinases in benign and malignant breast lesions

  1998cites this paper
• Analysis of Grb7 Recruitment by Heregulin-activated erbB Receptors Reveals a Novel Target Selectivity for erbB3*

  1998cites this paper
• Amplification of erbB-4 oncogene occurs less frequently than that of erbB-2 in primary human breast cancer.

  1998cites this paper
• Constitutively tyrosine phosphorylated p52 Shc in breast cancer cells: correlation with ErbB2 and p66 Shc expression

  1998cites this paper
• Transforming growth factor-beta in renal disease.

  1998cites this paper
• Transforming Growth Factor-β in Renal Disease

  1998cites this paper
• Recognition of activated CSF-1 receptor in breast carcinomas by a tyrosine 723 phosphospecific antibody

  1997cites this paper
• High c-erbB-3 protein expression is associated with shorter survival in advanced non-small cell lung carcinomas.

  1997cites this paper